Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HGS Cuts High Dose Albuferon In Phase III After Increased Pulmonary Events

This article was originally published in The Pink Sheet Daily

Executive Summary

Lower 900 mcg dose of albinterferon alfa-2b is on track for hepatitis C filing in fall 2009, Human Genome Sciences says.

You may also be interested in...



Albuferon ACHIEVE-1 Study Shows Non-Inferiority To Pegasys, But That Fails To Convince

Final Phase III study of Human Genome Sciences/Novartis' hepatitis C drug meets primary endpoint, but Pegasys does better numerically, leading to poor reception on the Street.

Albuferon ACHIEVE-1 Study Shows Non-Inferiority To Pegasys, But That Fails To Convince

Final Phase III study of Human Genome Sciences/Novartis' hepatitis C drug meets primary endpoint, but Pegasys does better numerically, leading to poor reception on the Street.

ACHIEVE-1 Study Shows Albuferon Non-Inferior To Pegasys; Questions Remain

With the March 9 release of the initial results of ACHIEVE-1, the final Phase III trial of Human Genome Sciences/Novartis' pegylated interferon Albuferon, Wall Street analysts have started to question the hepatitis C drug's market value. The trial failed to deliver outstanding efficacy results, and showed some signs of safety problems

Related Content

Topics

UsernamePublicRestriction

Register

PS066780

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel